Provider‐Prescribed Restrictive Diets in Patients With Eating Disorders Presenting for Gastroenterology Care
Neurogastroenterology & Motility · 2026-07 · 38 (7)
DOI: 10.1111/nmo.70397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 15.07.2026. Verfasst von Armand Amini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Neurointestinal Health, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Feeding and Eating Disorders, Gastrointestinal Diseases. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Introduction
Despite considerable evidence and patient demand, restrictive diets for gastrointestinal (GI) disorders may be harmful in those with comorbid eating disorders (EDs). We identified the frequency and characteristics of provider‐recommended restrictive diets among those with EDs seeking GI care.
Methods
Using a preexisting cohort of patients who had a GI encounter from 2010 to 2020 with a GI diagnosis and ED diagnosis (either diagnosed before or after initial GI encounter), we conducted a retrospective analysis of restrictive diet prescriptions within 12 months of initial GI consult as well as diet type, provider subspecialty, and types of ED and GI diagnoses.
Results
From a cohort of 610 patients, we found 285 patients meeting our inclusion criteria; 50 (17.5%) were prescribed restrictive diets within 12 months of their GI consult by GI providers. Disorders of gut‐brain interaction were the most common GI diagnoses overall ( n = 169, 59.3%). Of those with a pre‐existing ED ( n = 188), 30 (16.0%) were prescribed a restrictive diet, and of those with a subsequently diagnosed ED ( n = 97), 20 (20.6%) were prescribed a restrictive diet. Among patients with preexisting EDs, 69 (36.7%) were not in remission at the time of consultation. Of those with preexisting EDs who were prescribed a restrictive diet, 17/30 (57.7%) were not in remission.
Conclusion
We found that 16% of patients with an ED history were prescribed a restrictive diet by their gastroenterologist, including those not in remission. Further research is needed on the potential risk of restrictive diets in facilitating ED behavior.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Neurointestinal Health, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Armand Amini, Mia Dekel, Micaela Atkins, Isabelle Garcia-Fisher, Elizabeth N Madva, Helen Burton-Murray, Kyle Staller
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Amini, A., Dekel, M., Almeida, M. N., Atkins, M., Garcia-Fisher, I., Madva, E. N., Burton-Murray, H., & Staller, K. (2026). Provider‐Prescribed Restrictive Diets in Patients With Eating Disorders Presenting for Gastroenterology Care. Neurogastroenterology & Motility, 38(7). https://doi.org/10.1111/nmo.70397
Vancouver
Amini A, Dekel M, Almeida MN, Atkins M, Garcia-Fisher I, Madva EN, et al. Provider‐Prescribed Restrictive Diets in Patients With Eating Disorders Presenting for Gastroenterology Care. Neurogastroenterology & Motility. 2026;38(7). doi:10.1111/nmo.70397
BibTeX
@article{Amini2026,
author = {Amini, Armand and Dekel, Mia and Almeida, Mariana N and Atkins, Micaela and Garcia-Fisher, Isabelle and Madva, Elizabeth N and Burton-Murray, Helen and Staller, Kyle},
title = {Provider‐Prescribed Restrictive Diets in Patients With Eating Disorders Presenting for Gastroenterology Care},
journal = {Neurogastroenterology & Motility},
year = {2026},
volume = {38},
number = {7},
doi = {10.1111/nmo.70397}
}
EUVIMED